Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,586,524
  • Shares Outstanding, K 132,623
  • Annual Sales, $ 3,714 M
  • Annual Income, $ 313,750 K
  • EBIT $ 502 M
  • EBITDA $ 557 M
  • 60-Month Beta 0.35
  • Price/Sales 12.12
  • Price/Cash Flow 121.37
  • Price/Book 56.81

Options Overview Details

View History
  • Implied Volatility 41.02% (+0.27%)
  • Historical Volatility 43.13%
  • IV Percentile 41%
  • IV Rank 29.81%
  • IV High 68.01% on 04/08/25
  • IV Low 29.56% on 08/13/25
  • Expected Move (DTE 27) 25.85 (7.69%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 624
  • Volume Avg (30-Day) 631
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 28,319
  • Open Int (30-Day) 25,666
  • Expected Range 310.34 to 362.04

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 1.03
  • Number of Estimates 7
  • High Estimate 1.67
  • Low Estimate 0.64
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +334.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
298.00 +12.82%
on 02/12/26
376.87 -10.79%
on 01/22/26
-19.34 (-5.44%)
since 01/20/26
3-Month
298.00 +12.82%
on 02/12/26
479.79 -29.93%
on 12/03/25
-109.60 (-24.59%)
since 11/20/25
52-Week
205.87 +63.30%
on 04/09/25
495.55 -32.16%
on 10/20/25
+85.19 (+33.94%)
since 02/20/25

Most Recent Stories

More News
Alnylam: Q4 Earnings Snapshot

Alnylam: Q4 Earnings Snapshot

ALNY : 336.19 (-0.94%)
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress

− Achieved Fourth Quarter and Full Year 2025 Global Net Product Revenues of $995 Million and $2,987 Million, Respectively, Representing 121% and 81% Growth Compared to Same Periods in 2024 – ...

ALNY : 336.19 (-0.94%)
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2025...

ALNY : 336.19 (-0.94%)
Stocks Recover as Data Storage Companies and Chip Makers Rally

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.16%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.17%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.08%. March E-mini S&P...

AMAT : 375.38 (+1.50%)
B : 47.96 (-1.22%)
AVGO : 332.65 (-0.40%)
C : 116.00 (+0.39%)
HL : 24.02 (+5.40%)
HSIC : 79.57 (+3.61%)
CDE : 24.63 (+2.37%)
JPM : 310.79 (+0.89%)
AKAM : 94.17 (-14.07%)
ANIP : 77.77 (-0.42%)
$IUXX : 25,012.62 (+0.87%)
UNH : 290.00 (+0.02%)
Equity Indexes Recover Early Losses as Precious Metals Reach New Record Highs

The S&P 500 Index ($SPX ) (SPY ) today is up +0.28%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.15%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.55%. After opening lower, stock indexes...

B : 47.96 (-1.22%)
C : 116.00 (+0.39%)
HL : 24.02 (+5.40%)
HSIC : 79.57 (+3.61%)
CDE : 24.63 (+2.37%)
JPM : 310.79 (+0.89%)
AKAM : 94.17 (-14.07%)
ANIP : 77.77 (-0.42%)
$IUXX : 25,012.62 (+0.87%)
UNH : 290.00 (+0.02%)
ZNH26 : 112-300s (-0.03%)
MA : 526.41 (+1.18%)
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact

− Full Year 2025 Preliminary* Net Product Revenues of $2,987 Million (81% Growth vs. 2024), Driven Primarily by Preliminary* Total TTR Revenues of $2,487 Million (103% Growth vs. 2024) – ...

ALNY : 336.19 (-0.94%)
Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 44...

ALNY : 336.19 (-0.94%)
Stocks Slip as Bond Yields Rise

The S&P 500 Index ($SPX ) (SPY ) today is down -0.12%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.11%. March E-mini S&P futures...

C : 116.00 (+0.39%)
RARE : 22.72 (+4.08%)
SLB : 50.85 (-1.34%)
$IUXX : 25,012.62 (+0.87%)
ZNH26 : 112-300s (-0.03%)
OXY : 51.84 (+0.60%)
ESH26 : 6,923.25s (+0.67%)
FANG : 176.01 (+0.74%)
$DOWI : 49,625.97 (+0.47%)
SPY : 689.43 (+0.72%)
DIA : 496.08 (+0.47%)
INSM : 164.91 (+2.43%)
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics

New platform is expected to substantially increase manufacturing capacity and lower production costs, enabling investment in expanding pipeline FDA has accepted Alnylam’s enzymatic ligation...

ALNY : 336.19 (-0.94%)
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027

Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase agreements with certain...

ALNY : 336.19 (-0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic...

See More

Key Turning Points

3rd Resistance Point 352.85
2nd Resistance Point 349.37
1st Resistance Point 342.78
Last Price 336.19
1st Support Level 332.71
2nd Support Level 329.24
3rd Support Level 322.65

See More

52-Week High 495.55
Fibonacci 61.8% 384.89
Fibonacci 50% 350.71
Last Price 336.19
Fibonacci 38.2% 316.53
52-Week Low 205.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar